- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.01. | Vor Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.01. | Vor Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.12.25 | Vor Biopharma: Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors | 4 | GlobeNewswire (USA) | ||
| 18.12.25 | Vor Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.12.25 | Vor Biopharma: TD Cowen startet mit Kaufempfehlung und verweist auf Telitacicept-Potenzial | 11 | Investing.com Deutsch | ||
| 17.12.25 | Vor Biopharma stock initiated with Buy rating at TD Cowen on promising telitacicept potential | 1 | Investing.com | ||
| 15.12.25 | Vor Bio raises $150 million in private placement to fund clinical trials | 1 | Investing.com | ||
| 15.12.25 | Vor Bio announces $150M private placement | 5 | Seeking Alpha | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 15.12.25 | Vor Biopharma: Vor Bio Announces $150 Million Private Placement | 2 | GlobeNewswire (USA) | ||
| 09.12.25 | Vor Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.12.25 | JPMorgan initiates Vor Biopharma stock with Overweight rating on telitacicept potential | 17 | Investing.com | ||
| 09.12.25 | JPMorgan initiates Vor Biopharma stock with Overweight rating, $43 target | 6 | Investing.com | ||
| 13.11.25 | Vor Biopharma: Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 393 | GlobeNewswire (Europe) | Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected... ► Artikel lesen | |
| 12.11.25 | Vor Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.11.25 | Vor Biopharma Stock Sinks 48% | 9 | RTTNews | ||
| 11.11.25 | Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial | 12 | Benzinga.com | ||
| 11.11.25 | Vor Biopharma slumps 26%, prices $100M equity at $10 per share | 1 | Seeking Alpha | ||
| 11.11.25 | Vor Biopharma Prices Public Offering Of 10 Mln Shares At $10.00/shr | 3 | RTTNews | ||
| 11.11.25 | Vor Bio prices $100 million public offering of common stock | 6 | Investing.com | ||
| 11.11.25 | Vor Biopharma: Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock | 291 | GlobeNewswire (Europe) | BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the... ► Artikel lesen |
1 2 3 4 Weiter >>
77 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 42,000 | -0,47 % | Citizens senkt Kursziel für CRISPR Therapeutics auf 80 US-Dollar, bleibt aber optimistisch | ||
| EDITAS MEDICINE | 1,645 | -1,26 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| GERON | 1,190 | +3,34 % | Geron Corporation Provides 2026 Financial Guidance | 2026 RYTELO (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,080 | -2,92 % | SOL Global Investments Corp.: SOL Global Announces Settlement of Outstanding Debentures | Toronto, Ontario--(Newsfile Corp. - January 21, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCD) (FSE: 9SB0) ("SOL" or the "Company") is pleased to announce that it has satisfied its... ► Artikel lesen | |
| TRINITY BIOTECH | 0,827 | -7,45 % | Trinity Biotech plc: Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives | - Arrangements provide increased near-term funding and extend maturity of credit agreement to early 2027 - Equity settlement mechanisms also agreed for milestone payments and contingent acquisition... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,956 | -4,40 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates |
Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 7,490 | -1,19 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| OVID THERAPEUTICS | 1,390 | +5,30 % | Ovid Therapeutics Inc.: Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer | NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need,... ► Artikel lesen | |
| CERVOMED | 4,240 | 0,00 % | CervoMed Inc.: CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies | Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low... ► Artikel lesen | |
| EQUILLIUM | 1,180 | -1,50 % | Equillium, Inc.: Equillium Announces Leadership and Corporate Updates | LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 8,870 | -1,11 % | Deep Dive Into 4D Molecular Therapeutics Stock: Analyst Perspectives (5 Ratings) | ||
| CABALETTA BIO | 2,570 | -6,55 % | Cabaletta Bio-Aktie: Wird sie 2026 erneut zum Biotech-Highflyer? | Die Aktie des ehemaligen sharedeals.de-Tenbaggers Cabaletta Bio wird seit geraumer Zeit wieder mit vorsichtigem Optimismus begleitet, während das Biotech-Unternehmen versucht, eine gentechnisch veränderte... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 24,760 | -11,24 % | Trip.com, Regencell Bioscience, And Atlassian Are Among Top 10 Large Cap Losers Last Week (Jan. 12-Jan. 16): Are the Others in Your Portfolio? | ||
| GENERATION BIO | 5,590 | -0,36 % | XOMA Royalty Corporation Enters into Agreement to Acquire Generation Bio Co. | - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery... ► Artikel lesen | |
| LONGEVERON | 0,555 | -4,26 % | Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) | ELPIS II top-line trial results are anticipated in the third quarter of 2026Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS... ► Artikel lesen |
Das Unternehmen VOR BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -1,000 (-7,14 %) liegt der Kurs bei 13,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.